Fig. 1From: Pharmacodynamics of nine generic products of amikacin compared with the innovator in the neutropenic mouse thigh infection modelReliability of the neutropenic murine thigh infection model with the innovator of amikacin (BMS) in two independent experiments. The non-significant P value (0.393) from global curve fitting analysis (CFA) indicates that the underlying populations are better described by a single curve, confirming the model’s reliability for testing therapeutic equivalenceBack to article page